|
|
|
- こうざぶろう あさぶき
- 5 years ago
- Views:
Transcription
1 IMUSERA
2
3
4 4
5 1.56mg.5mg D mm 5.8mm.96g FTY.5mg FTY.5mg OH NH2 OH H3C HCI 5
6 6
7 7 BCG Torsades de pointes a 2 2
8 8
9 9
10 p.6logistic regression model T p.4logistic regression model Gd 5 48 MeanSD p.1negative binomial model 2EDSS 1.1
11 / CI p.47 negative binomial model 2 EDSS log-rank 11
12 % 89.6% 64.3% 88.3% 89.7% 65.1% p.1 logistic regression model T2MRI MeanSD p.1 negative binomial model
13 / CI p.1negative binomial model 2EDSS p.1log-rank 13
14 p.26 log-rank MeanSD p.6 p=.26 p.1 rank ANCOVA 14
15 % % IFN-1a IFN-1a361 p.1 logistic regression model MeanSD p.4 negative binomial regression 2 EDSS
16 / CI IFN-1a431 p.1negative binomial model 2EDSS % % IFN-1a p.1log-rank 16
17 IFN-1a359 MeanSD p.1wilcoxon 17
18 18 % % 38 % %
19 19 % % % %
20 2 % 2,344 1, % 3,45 % %
21 21 % %
22 22 % %
23 23 % %
24 24 % % % %
25 ng/ml MeanSD 1.25mgn=6 2.5mgn=7 5mgn= Tmax h Cmax ng/ml AUClast ngh/ml T1/2 days 1.25mgn= mgn= mgn= mgn= mgn= mgn= MeanSD : 25
26 1 ng/ml ng/ml MeanSD n= Tmax h Cmax ng/ml AUCtau ngh/ml T1/2 days MeanSD : n=6 26
27 ng/ml mg.5mg 1.25mg 1.25mg MeanSD.5mg 1.25mg.5mg 1.25mg ng/ml 27
28 ng/ml 2. ng/ml 2. MeanSD n= Tmax h Cmax ng/ml AUCinf ngh/ml T1/2 h a a a a MeanSD : n=29a : n=27 28
29 ng/ml 1.5 n=9 n=9 ng/ml 1.5 MeanSD n=9 n= Tmax h Cmax ng/ml AUCinf ngh/ml T1/2 h a 6631 a 955 a 1146 a MeanSD : n=9a : n=5 29
30 ng/ml n=8 n=8 n= ng/ml n=6 n= Tmax h Cmax ng/ml AUCinf ngh/ml T1/2 days a mg a b mg c c c c , MeanSD :, : AUClasta : n=8, b : n=16, c : n=6 3
31 31 NH2 FTY72 OH HO NH2 FTY72-P (S)-enantiomer(AML629) OH HO HO O O P NH2 M1 OH COOH HO NH2 M2 OH COOH HO NH2 M3 OH COOH HO NH2 M4 OH COOH HO NH2 M12 OH OH HO (not observed) NH +oxygen M29 OH O HO NH -2H2 M27 OH O HO NH M3 OH O HO NH M28 OH O HO COOH NH2 Gluc. M22 OH HO
32 /mm 3 3, 2, 1,.5mgn mgn54 n cells/l n24 n24 56
33 % n12 n15 % n12 n
34 1.5mg1 bpm mg 5mg n6 n
35 bpmbpm mgn mgn54 n mgn mgn54 n57 35
36 bpmmean95ci bpm n12 n n12 n13 1 n12 n n12 n13 bpm
37 37 S1P1 S1P G G S1P1 -P -P S1P -P S1P1 nmol/l S1P1 nmol/l Th17Th1 S1P1 nmol/l S1P1 Th17Th1 S1P1 -P S1P1 nmol/l S1P1 nmol/l S1P1 nmol/l S1P1
38 38
39 S1P S1P1 S1P2 S1P3 S1P4 S1P % % % Control S1P1 mg/kg 39
40 MeanSD rm-ifn ## ## mg/kg.3mg/kg rm-ifn 3 IU/ rm-ifn 1 IU/ n=12 : p<.5: p<.1vs Steel : p<.1vs ##: p<.1 vs rm-ifn 3 IUWilcoxon : p<.5: p<.1 vs rm-ifn 1 IUWilcoxon 4
41 : p.1tukey test AD HE BCE 41
42 EAE EAE EAE EAE EAE EAE 42
43 13Hz 35-36C 151ng/mL herghek239 herg 1255ng/mL 25ng/mL 5ng/mL herghek239 herg 352C.5mol/L 2ng/mL 2.5mol/LhERG 25% herghek239 1 herg 352C AML629.31mol/L 14ng/mL 1mol/L.4mol/L herg18% mol/l ng/mL 3 1GLP AML629 : FTY72S- 43
44 ph mg/kg 1mg/kg 1mg/kg 1mg/kg SBP T 3mg/kg 1mg/kg-29% 3mg/kg 1mg/kg.111 Irwin mg/kg 1 SBP :
45 mg/kg mg/kg >2 1 : mg/kg/ mg/kg/ : 45
46 2 mg/kg/ mg/kg/ < < : : 46
47 47
48 25/6%RH PTP 36 3/65%RH PTP 12 4/75%RH PTP 6 5 PTP 1 12luxh2Wh/m 2 ICHQ1AR Q1B
49 49
50 5
51
52 IMUSERA
エディロールカプセルインタビューフォーム
2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/
ほんぶん－第６章.indd
m,m ...,,,..... BCG - /.... T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S
6„”“ƒ„û−G33
C O N T E N T S 2,706 3,183 3,957 0100101 22 10 21 1,414 1,663 2,250 0601603102 2000
A5_Catalog-US-JN_ indd
66 22 g 13 g 8 g 5 g 7500 IU 150% 300 mg 600 IU 100 IU 80 mcg 3 mg 3.5 mg 40 mg 4 mg 500 mcg 12 mcg 300 mcg 20 mg 1000 mg 150 mcg 400 mg 15 mg 105 mcg 2 mg 2 mg 180 mcg 125 mcg 15 mg 3.6 g ** 3.8 g **
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
タミフルインタビューフォーム
2008 1 20 87625 IF 1998 9 75 3% 2 1 75mg 1 g 30mg Oseltamivir Phosphate 2000 12 12 2001 2 2 2001 2 2 2002 1 17 2002 4 26 2002 7 31 IF 2008 1 O H 2 N O H O CH 3 H 3 C N H H 3 PO 4 H H O H 3 C CH 3
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
物理化学I-第11回(13).ppt
I- 11-1 10 10.5 H 3 O + (aq) + OH (aq) + Na + (aq) + Cl (aq) Na + (aq) + Cl (aq) + 2H 2 O(l) - or - [A] V A = [B] V B 22 mol dm 3 equiv dm 3 - H 2 SO 4 (aq) + 2NaOH(aq) 2Na + (aq) + SO 4 2 (aq) + 2H 2
JA2008
A1 1 10 vs 3 2 1 3 2 0 3 2 10 2 0 0 2 1 0 3 A2 3 11 vs 0 4 4 0 0 0 0 0 3 6 0 1 4 x 11 A3 5 4 vs 5 6 5 1 0 0 3 0 4 6 0 0 1 0 4 5 A4 7 11 vs 2 8 8 2 0 0 0 0 2 7 2 7 0 2 x 11 A5 9 5 vs 3 10 9 4 0 1 0 0 5
Microsoft Word - 目次注意事項2.doc
I II 2009 1. 2. 12 50 3. 1. 2. 3 ( 0.1g, 0.01g, 0.001g ) 3. 4. 1. 2. ()A4 3. 000005 19 5 11 () 19 5 15 () EDTA " # $ 1000 500 =... mol/l Web 1) p.159 2) 1987pp.14-15 3) 1989pp.58-60 4) http://www.chem.zenkyo.h.kyoto-u.ac.jp/operation/
無印良品のスキンケア
2 3 4 5 P.22 P.10 P.18 P.14 P.24 Na 6 7 P.10 P.22 P.14 P.18 P.24 8 9 1701172 1,400 1701189 1,000 1081267 1,600 1701257 2,600 1125923 450 1081250 1,800 1125916 650 1081144 1,800 1081229 1,500 Na 1701240
QA_H2+3_作2
1 Q 1 Q 2 Q 3 Q 4 Q 5 Q 6 Q 7 6 7 8 10 10 11 12 Q 8 Q 9 Q 10 Q 11 Q 12 Q 13 Q 14 Q 15 Q 16 Q 17 Q 18 Q 19 14 15 16 17 18 18 20 22 24 26 28 30 Q 20 Q 21 Q 22 Q 23 Q 24 Q 25 Q 26 Q 27 Q 28 32 33 34 35 36
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
untitled
20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20
土壌の観察・実験テキスト −土壌を調べよう！−
( ) 2006 7 20 i 21 1962 1969 1987 1992 2005 65 1972 1977 1997 1977 1998 1982 1998 2002 2004 2005 SPP 1999 ii 1 g cm m 6378km ( ) 4.2, 4.3 5.1 7.1 8.1 4.1 7.3, 7.4 7.1 1 2 7.1 8.2 2 5 6 1, 2 2.3 4.2, 4.3
本組よこ／根間：文１１－１１＿Ｐ１３１－１５８
131 132 pp 133 134 a b 135 S pp S 136 a p b p S 137 p S p p H a p b 138 p H p p 139 T T pp pp a b c S a Sp a 140 b c d Sp a b c d e Spp a 141 b c d S a b c d S pp a b 142 c d e S S S S S S S 143 S S S
untitled
Kw 1-12 1-13 Kw van t Hoff 0 0 0 H S d ln K H ln K = + = RT R d(1/ T ) R ln KW 1/T H 0 /R H 0 = 51.0 kj mol -1 HCl H + + Cl - H2O H + + OH - [] [H + ] [OH - ]=10-14 M 2 25 OH - x OH - [OH - ]=x [H + ]
4 1 Ampère 4 2 Ampere 31
4. 2 2 Coulomb 2 2 2 ( ) electricity 2 30 4 1 Ampère 4 2 Ampere 31 NS 2 Fleming 4 3 B I r 4 1 0 1.257 10-2 Gm/A µ 0I B = 2πr 4 1 32 4 4 A A A A 4 4 10 9 1 2 12 13 14 4 1 16 4 1 CH 2 =CH 2 28.0313 28 2
O157 6/23 7/4 6 25 1000 117,050 6 14:00~15:30 1 2 22 22 14:30~15:30 8 12 1 5 20 6 20 10 11 30 9 10 6 1 30 6 6 0 30 6 19 0 3 27 6 20 0 50 1 2 6 4 61 1 6 5 1 2 1 2 6 19 6 4 15 6 1 6 30 6 24 30 59
1 2 http://www.japan-shop.jp/ 3 4 http://www.japan-shop.jp/ 5 6 http://www.japan-shop.jp/ 7 2,930mm 2,700 mm 2,950mm 2,930mm 2,950mm 2,700mm 2,930mm 2,950mm 2,700mm 8 http://www.japan-shop.jp/ 9 10 http://www.japan-shop.jp/
1 1 36 223 42 14 92 4 3 2 1 4 3 4 3429 13536 5 6 7 8 9 2.4m/ (M) (M) (M) (M) (M) 6.67.3 6.57.2 6.97.6 7.27.8 8.4 5 6 5 6 5 5 74 1,239 0 30 21 ( ) 1,639 3,898 0 1,084 887 2 5 0 2 2 4 22 1 3 1 ( :) 426 1500
1 C 2 C 3 C 4 C 1 C 2 C 3 C
1 e N >. C 40 41 2 >. C 3 >.. C 26 >.. C .mm 4 C 106 e A 107 1 C 2 C 3 C 4 C 1 C 2 C 3 C 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124
平成２４年財政投融資計画ＰＤＦ出後８／０１６‐０３０
24 23 28,707,866 2,317,737 26,390,129 29,289,794 2,899,665 24 23 19,084,525 21,036,598 1952,073 24 23 8,603,613 8,393,427 967,631 925,404 202,440 179,834 217,469 219,963 66,716 64,877 3,160,423 2,951,165
第18回海岸シンポジウム報告書
2011.6.25 2011.6.26 L1 2011.6.27 L2 2011.7.6 2011.12.7 2011.10-12 2011.9-10 2012.3.9 23 2012.4, 2013.8.30 2012.6.13 2013.9 2011.7-2011.12-2012.4 2011.12.27 2013.9 1m30 1 2 3 4 5 6 m 5.0m 2.0m -5.0m 1.0m
1 911 34/ 22 1012 2/ 20 69 3/ 22 69 1/ 22 69 3/ 22 69 1/ 22 68 3/ 22 68 1/ 3 8 D 0.0900.129mm 0.1300.179mm 0.1800.199mm 0.1000.139mm 0.1400.409mm 0.4101.199mm 0.0900.139mm 0.1400.269mm 0.2700.289mm
液晶ディスプレイ取説TD-E432/TD-E502/TD-E552/TD-E652/TD-E432D/TD-E502D
1 2 3 4 5 6 7 1 2 3 4 5 6 7 2 2 2 1 1 2 9 10 11 12 13 14 15 16 17 1 8 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10 9 11 12 13 13 14 15 16 17 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 11 12
000-.\..
1 1 1 2 3 4 5 6 7 8 9 e e 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 10mm 150mm 60mm 25mm 40mm 30mm 25 26 27 1 28 29 30 31 32 e e e e e e 33 e 34 35 35 e e e e 36 37 38 38 e e 39 e 1 40 e 41 e 42 43
(1519) () 1 ( ) () 1 ( ) - 1 - - 2 - (1531) (25) 5 25,000 (25) 5 30,000 25,000 174 3 323 174 3 323 (1532) () 2 () 2-3 - - 4 - (1533) () 1 (2267)204 () (1)(2) () 1 (2267)204 () (1)(2) (3) (3) 840,000 680,000
[mm] [mm] [mm] 70 60 50 40 30 20 10 1H 0 18 19 20 21 22 23 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1 2 3 4 5 6 7 8 9 10 11 12 60 50 40 30 20 10 0 18 19 20 21 22 23 24 1 2 3 4
A E A A A A E A E EAE EAE EA AE E AE E A AE EA AE EA AE EA AE EA AE EAE EAE EAE EAE E AE E A AE EA AE EAE E AE EA AE E AE E A AE E E A AE E E A AE EA
A E A A A A E A E EAE EAE EA AE E AE E A AE EA AE EA AE EA AE EA AE EAE EAE EAE EAE E AE E A AE EA AE EAE E AE EA AE E AE E A AE E E A AE E E A AE EA AE EAE EA E AE EA AE EA AE EAE E AE EAE E AE EA AE
1
1 100 50/60Hz 100 50/60Hz 2 3 4 Windows 4.0SP3 Windows98 4.0SP3 800600 256 1024768 SETUP.EXE 5 [ ] 6 [ OK] [ ] 7 [ OK] [ ] 8 [ OK] [ ] 9 [ ] [ ] [ ] Enter Enter Windows Alt MP-60 10 [ ] F4 [ ] [ ] [ ]
1) 1) 1 R 2 3 4 5 6 3) 4) 5) Punch 7 10g/mL(63.6mol/L) 20mg/kg 78 5 23 Cmax 250mg 3.9g/ml 500mg 6.0g/ml1000mg 8g/ml2000mg 15g/ml 33.4 110-116mL/min 1,8) 8 95 9 10 ( ) 11 desa 12 13 12) 2.5 5 19 Rec assayames
取扱説明書[NE-202]
![取扱説明書[NE-202]](/thumbs/39/20478473.jpg "取扱説明書[NE-202]")
NE-202 13.3 m m 1 2 3 m 4 5 6 7 a a a 8 9 10 11 12 a a a a 13 14 15 16 17 2.4 FH 1/XX 4 18 19 20 21 22 23 24 25 26 27 1 2 3 4 5 6 m 7 h 8 r 9 a P b c d e f g h i j ud k l m n o 28 29 30 31 32 33 34 35
2010 1 1 7 2 16 2 2 06in 3 3 錆 錆 06in 4 4 0.1 5 5 HCl Cl NaOH H Cl O 2 H H 2 O NaCl Na OH H 2 O NaCl 2010 6 6 ph3.0 30 mg/l 30 1 O-157 H7 2010 7 7 100 Cl 80 60 40 20 HClO ClO CL ph 10 100,000ppm 12 01
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
g 51 52
10 12 A 12 C 12 13 13 13 13 16 16 18 18 18 23 23 23 23 23 A 24 25 25 26 28 28 30 32 38 38 41 42 43 10 43 11 45 48 48 120g 51 52 12 3 12 3 350g 120g 1 7 10 260g 90g 90g 30g 9 11 2 gg1 g 1 120g 10 1 12 6
Vol. 4, No
1 0.005 71 2 0.005 72 3 0.005 73 4 0.005 74 5 0.005 KRM 75 6 0.005 76 7 0.005 77 8 0.005 78 9 0.005 79 10 0.005 80 11 0.005 TS 81 12 0.005 TOA 82 13 0.005 83 14 0.005 84 15 0.005 NS 85 16 0.005 86 17 0.005
mg (1) (2) QT (3) 1 400mg 1 1 2
17 8 10 400mg 14 9 30 1 400mg 1 C21H24FN3O4 HCl 437.89 1 6 8 7 [(4aS, 7aS) [3,4 b] 6 ] 4 1,4 3 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridine -6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic
日本化学療法学会雑誌第54巻第S-1号
β β β Key words β β I HP- -CD CHR RHC R R R R CHR R R R R RHC R R R CHR R R R RHC CHR R H CH CH Fig.. Structuralformulaofhydroxypropyl-β -cyclodextrin(hp-β -CD). CH n H β β β β Table-. Dosageandadministration(Singleadministrationstudy)
09_organal2
4. (1) (a) I = 1/2 (I = 1/2) I 0 p ( ), n () I = 0 (p + n) I = (1/2, 3/2, 5/2 ) p ( ), n () I = (1, 2, 3 ) (b) (m) (I = 1/2) m = +1/2, 1/2 (I = 1/2) m = +1/2, 1/2 I m = +I, +(I 1), +(I 2) (I 1), I ( )
本組よこ／根間：文１１－０２９＿Ｐ３７７‐４０８
377 378 a b c d 379 p M NH p 380 p 381 a pp b T 382 c S pp p 383 p M M 384 a M b M 385 c M d M e M 386 a M b M a M 387 b M 388 p 389 a b c 390 391 a S H p p b S p 392 a T 393 b S p c S 394 A a b c d 395
untitled
1.4 特 許 状 況 - 1 - - 2 - 1.5 起 原 又 は 発 見 の 経 緯 及 び 開 発 の 経 緯 FCT CT RH ... 1.5-1... 1.5-1... 1.5-1... 1.5-1... 1.5-2... 1.5-2... 1.5-2... 1.5-3...1.5-4... 1.5-5 i 10mg FCT 1 1 6 15 5mg CT 1 1 2 6 4mg CT
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
PRT-A01A_1604_g
PTP D AMX AMZ MALT MALT PC CYPC ACYPA ph ph ph ph ALTGPT ASTGOT LDH AlP X ToxicEpidermalecrolysisTE StevensJohnson BU CKCPK ASTGOT ALTGPT AlPGTP LDH BU TSH CK CPK ALTGPT ASTGOT GTP AlPLDH PTPPTP PTP C
温泉の化学 １
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
後期化学_04_酸塩基pH
2011 ( ) ph H3O + H + H3O + HCl H3O + HCl + H2O H3O + + Cl HCl H + + Cl OH OH NaOH OH NaOH Na + + OH NH3 OH NH3 + H2O NH4 + + OH 1 H + OH H + H + * 1 NH3 HCl NH4Cl NH4Cl NH3 + Cl NH3 + HCl NH4 + + Cl.
untitled
Data cleaning Original datan=8479 NCC/ptkgN=7958 NCC10x10E628 8139 NCC/kgPage 1-2) Covariate cleaningcovariate Page Page5-8 Kaplan-Meier method, Log-rank, Cox hazard model Overall survival Cumulative incidence
Microsoft Word - 高橋＿国試講習会2006m.doc
2006 19 150 20 200 19 80 2 70 1 45 1 1 30 20 105 2 40 1 1 31 95 2 25 1 1 32 1. 2. 3. 4. 5. 1 [] 25 12.5% 2006/3 6 2 1 2 3 7 A a b c d 11 e B a b c d C a b c D a b E a b c d 2 15 16 17 18 19 20 2001 2002
価格表-1左頁-apl-C2
20144 RE-7301RE-8353 2014-2016 201014 2013-2015 201014 2014-2016 P.1 P.3 P.5 P.17 P.28 P.29 1 SV Standard Value SV RAL 0.2mg/ 0.1mg/kg VOC 30mg/kg 20mg/kg 5mg/kg TVOC100g/gTEX10g/g 300CDBP 1571 282 3 1571
Taro9-医薬品目次２０１２－１.PDF
5 0.1% 11 250mg 10 20mg 10 5ml 19 0.05% 13 1.25mg 10 1%5ml 19 10mg 10 0.2%100ml 18 25%50ml 9 2mg 17 5%250ml 9 20%25g 20 500 g 11 4 10g 20 Cap150mg 1 200mg 0 Cap90mg 5 20mg 10 10% 5 18 10mg 10 3%30g 20
１ 発病のとき
3 2 1996 1996 539 3 1953 1954 1960 1961 1975 1976 1990 1990 1996 1953 1960 2001 5 11 1975 1990 1996 1 1953 1951 26 112 3 126 127 3 130 22 223 518 2 519 2 623 2 821 540 3 9 27 255 1 1026 2 114 1110 1111
こんにちは由美子です
1 2 . sum Variable Obs Mean Std. Dev. Min Max ---------+----------------------------------------------------- var1 13.4923077.3545926.05 1.1 3 3 3 0.71 3 x 3 C 3 = 0.3579 2 1 0.71 2 x 0.29 x 3 C 2 = 0.4386
橡DI月報１７8.PDF
2002.5.10. DI 22-2668 HCV HCV 1 1 375mg/ 13 60mg 20mg 1 20mg 1 750mg 1 400mg 3 1 2 7 IAB IAB IAB IAB IAB HIV ( ) HIV CYP3A4 HIV ( ) CYP3A4 WBC CK CK 1) 2) Torsades de Pointes K ) ALT AST -GTP CYP2C9 CYP2C19
第4次酸性雨全国調査報告書(平成16年度) -(Ⅱ)付表編-
1.12.24 P. 5.4.3.1 NO NOP. 5.4.3.2P. 5.4.3.3 P. 5.4.3.4 P. 2.18 2.19 P. 2.20 P. 2.21 P. P. 5.5.2.11 SOA P. 5.5.2.12 NO B A B 1.1 16 mm FRS Vol. 31 42006 1.2 ph 16 FRS ms/m FRS 1.3 16 Vol. 31 42006 μmol/l
2 Zn Zn + MnO 2 () 2 O 2 2 H2 O + O 2 O 2 MnO 2 2 KClO 3 2 KCl + 3 O 2 O 3 or 3 O 2 2 O 3 N 2 () NH 4 NO 2 2 O + N 2 ( ) MnO HCl Mn O + CaCl(ClO
1 [1]. Zn + 2 H + Zn 2+,. K Ca Na Mg Al Zn Fe Ni Sn Pb H Cu Hg Ag Pt Au H (H + ),,. [2] ( ) ( ) CO 2, S, SO 2, NH 3 () + () () + () FeS Fe S ( ) + ( ) ( ) + ( ) 2 NH 4 Cl + Ca(OH) 2 Ca O + 2 NH 3,.,,.,,.,.
物理化学I-第12回(13).ppt
I- 12-1 11 11.1 2Mg(s) + O 2 (g) 2MgO(s) [Mg 2+ O 2 ] Zn(s) + Cu 2+ (aq) Zn 2+ (aq) + Cu(s) - 2Mg(s) 2Mg 2+ (s) + 4e +) O 2 (g) + 4e 2O 2 (s) 2Mg(s) + O 2 (g) 2MgO(s) Zn(s) Zn 2+ (aq) + 2e +) Cu 2+ (aq)
16 23 270 5 1 2 3 1 2 3 1 2 3 6 5 54 44 9 9 4,000 118 7 5 JA 8 1 1 2 16 48,000 1 1 1 1 2 2 3 1, 312. 87 4 5 10 3 31 6 10 4 25 7 3 1 2 8 2 495. 84 1 296. 49 2 199. 35 1 124. 62 54. 50 28. 80 34. 17 54.
有機性産業廃棄物の連続炭化装置の開発
( ) Development of the apparatus conveyer type which carbonizes continuously organic industrial waste (About the form of blade in conveyer) 1055047 1 1-1 1 1-2 1-3 2 2 2-1 2-2 2-3 2-4 7 3 3-1 20 3-2 3-3
% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
1
I II II 1 dw = pd = 0 1 U = Q (4.10) 1K (heat capacity) (mole heat capacity) ( dq / d ) = ( du d C = / ) (4.11) du = C d U = C d (4.1) 1 1 du = dq + dw dw = pd dq = du + pd (4.13) p dq = d( U + p ) p (4.14)